

**FISA DE VERIFICARE A INDEPLINIRII STANDARDELOR MINIME NATIONALE  
in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA TITLURILOR DIDACTICE DIN ÎNVĂȚĂMÂNTUL SUPERIOR ȘI A GRADELOR PROFESIONALE DE CERCETARE – DEZVOLTARE**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
1	<b>Didactică și profesională</b>	<b>1.1. cărți și capitol în cărți de specialitate (cu ISBN)</b>  <b>– autor / coautor</b>	<b>Criterii obligatorii:</b>  1 capitol in tratat internațional = 1 carte națională;  1 carte internațional = 3 cărți naționale  <b>Conferențiar – 1 carte de specialitate sau cel puțin 3 capitole într-un tratat</b>  Profesor – 2 cărți (din care una ca prim autor sau autor unic) sau 6 capitole în tratate, de la ultima promovare		
			<b>Îndeplinire:</b>	National	Carti ca autor 1. Victoria Burtea – <i>Manual de semiologie psihiatrică</i> , Casa de Editură Venus, Iași, 2003.  2. Victoria Burtea – <i>Manual de psihiatrie clinică</i> , Casa de Editură Venus, Iași, 2003  3. Victoria Burtea – <i>Schizofrenia: repere clinico-terapeutice</i> , Editura Universității „Transilvania”, Brașov, 2004  4. Victoria Burtea – <i>Breviar de psihopatologie</i> . Editura Universității „Transilvania”, Brașov, 2014

5. Victoria Burtea, Petru Ifteni – *Psihopatologie – Cazuri clinice*, Editura Universității „Transilvania”, Brașov,

**Criteriu indeplinit**

1.2. cărți și  
capitole în cărți  
de specialitate  
(cu ISBN) -  
coordonator

*Îndeplinire:* internaționale  
naționale

2

*Cercetare*

2.1. articole in  
extenso in  
reviste cotate  
ISI Thomson  
Reuters

*Criterii obligatorii:*

articole in reviste cu factor de impact, in calitate de autor principal, de la ultima promovare

Profesor – minim 6 articole

**Conferențiar – minim 3 articole**

*Îndeplinire:*

1. Moga M , Burtea V, Ifteni P, Socioeconomic status and psychological factors involved in suicide, Revista de Cercetare si Interventie Sociala, 2014, vol. 45, pp. 230- 239

2. Szalontai A, Burtea V, Ifteni P. Blood Alcohol Concentration in Suicide: A 10 years Study, Revista de Cercetare si Interventie Sociala, 2014, vol. 46, pp. 144-151

3. Szalontai A, Burtea V, Ifteni P. Predictors of Institutionalization in Dementia, Revista de Cercetare si Interventie Sociala, 2015, vol. 49, pp. 249-257

4. Moga MA, Irimie M, Oanta A, Pascu A, Burtea V. Type-specific prevalence of human papillomavirus by cervical cytology among women in Brasov, Romania. Asian Pacific Journal of Cancer Prevention. 2014. Vol./is 15/16 (6887-92).

5. Ifteni P., Burtea V., Szalontay A.S., Moga M.A. Ethics of Treatment in Early Psychosis, Revista Romana de Bioetica, in press

6. Moga MA, Arvatescu CA, Pratilas GC, Bigiu NF, Dinas K , Burtea V. The Role of GaslessLaparoscopy in Differential Diagnosis of Acute Abdomen. Hippokratia, in press, 2015.

**Criteria indeplinit**

**2.2. articole in extenso in reviste si volumele unor manifestări științifice indexate ISI sau in alte BDI**

**Criteria obligatorii:**

Profesor – minim 25 articole, din care 5 de la ultima promovare

**Conferențiar – minim 15 articole din care 3 de la ultima promovare**

1 articol ISI cu I.F. < 1 = 3 articole in reviste indexate BDI dar nu si invers

1 articol ISI cu I.F. ≥ 1 = 5 articole in reviste indexate BDI dar nu si invers (I.F. = impact factor)

**Îndeplinire:**

**Articole ISI cu I.F ≥ 1**

1. Hans Rittmannsberger, Norman Sartorius, Victoria Burtea, Nora Căpraru, Pavel Cernak, Mojka Dernovcek, Ionescu Dobrin, Rosa Frater, Jozef Hasto, Mieta Hategan, Manfred Haushofer, J. Kafka, Siegfried Kasper, Rodica Macrea, Ludvik Nabelek, Peter Nawka, Vladimir Nowotny, Thomas Platz, Adela Pojar, Christoph Silberbauer, Matyas Trixler, Johannes Wancata, Elmar Windhager, Hans-Georg Zapatoczky, Robert Zochling - Changing aspects of psychiatric inpatient treatment. A census investigation in five European countries, European Psychiatry, 19 (2004), 483-488

2. Steven G. Potkin, Georges M. Gharabawi, Andrew J. Greenspan, Rammy Mahmoud, Colette Kosik-Gonzalez, Marcia F.T. Rupnow, Cynthia A. Bossie, Michael Davidson, Victoria Burtea, Young Zhu, Jintendra K. Tivedi – A double blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalisation, Schizophrenia Research 85 (2006), 254-265

3. Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder, J Affect Disord. 2014

Sep;166:168-72. doi:10.1016/j.jad.2014.04.020. Epub 2014 May 20.

4. Ifteni P, Correll CU, Burtea V, Kane JM, Manu P., Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients, Schizophr Res. 2014 May;155(1-3):72-6. doi: 10.1016/j.schres.2014.03.011. Epub 2014 Apr 4.

5. Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P, Effectiveness and safety of rapid clozapine titration in schizophrenia, Acta Psychiatr Scand. 2014 Jul;130(1):25-9. doi:10.1111/acps.12241. Epub 2013 Dec 20.

6. Ifteni P, Moga MA, Burtea V, Correll CU. Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Therapeutics and clinical risk management. 2014. 10:901-904

#### **Articole in reviste indexate BDI**

1. Burtea V., Ifteni P., Sumedrea A.G., Mosoiu C. The treatment option in the current practice in acute exacerbation of schizophrenia in Brasov county. Romanian Journal of psychopharmacology, 2011, vol11, Issue 2, pp: 99-108  
<http://www.psychopharma.eu/reviste/Vol.%2011,%20Nr.%202.pdf>

2. Ifteni P., Burtea V., Teodorescu A. Patterns of antipsychotic use model in treatment of Bipolar I disorder – a 12 months observational study. Bulletin Of The Transilvania University, vol 4(53), Series VI, NO.1/2011, pp:73-76  
[http://webbut.unitbv.ro/bu2011/Series%20VI/BULETIN%20VI%20PDF/13\\_IFTENI.pdf](http://webbut.unitbv.ro/bu2011/Series%20VI/BULETIN%20VI%20PDF/13_IFTENI.pdf)

3. **Burtea V.**, Ifteni P., Constantin D. Consideration about treatment noncompliance in schizophrenia and hospital addressability. Bulletin Of The Transilvania University, vol 4(53), Series VI, NO.1/2011, pp:67-72  
[http://webbut.unitbv.ro/bu2011/series%20vi/buletin%20vi%20pdf/12\\_burtea\\_mare.pdf](http://webbut.unitbv.ro/bu2011/series%20vi/buletin%20vi%20pdf/12_burtea_mare.pdf)

4. Burtea V., Ifteni P., Teodorescu A., Rogozea L. Clozapine in treatment of schizophrenia. Bulletin Of The Transilvania University, vol 4(53), Series VI, NO.2/2011,pp:111-116  
[http://webbut.unitbv.ro/BU2011/Series%20VI/BULETIN%20VI/16\\_BURTEA.pdf](http://webbut.unitbv.ro/BU2011/Series%20VI/BULETIN%20VI/16_BURTEA.pdf)

5. Ifteni P., Burtea V., Ifteni G., Taran L., Rogozea L. Admission to the psychiatric emergency services of patients with alcohol- related mental disorder. Bulletin Of The Transilvania University, vol 4(53), Series VI, NO.2/2011, pp:117-122 [http://webbut.unitbv.ro/BU2011/Series%20VI/BULETIN%20VI/17\\_IFTENI.pdf](http://webbut.unitbv.ro/BU2011/Series%20VI/BULETIN%20VI/17_IFTENI.pdf)

6. **Burtea V.**, Rogozea L., Ifteni P. Ethical Significance of Lack of Insight and Informed Consent in Schizophrenia. Bulletin Of The Transilvania University, vol 5(54), Series VI, NO.1/2012, pp:43-48 [http://webbut.unitbv.ro/BU2012/Series%20VI/BULETIN%20VI%20PDF/07\\_BURTEA\\_ROGOZEA.pdf](http://webbut.unitbv.ro/BU2012/Series%20VI/BULETIN%20VI%20PDF/07_BURTEA_ROGOZEA.pdf)

7. **Burtea V.**, Ifteni P., Pascu A. The QTC Interval in Patients Treated with Antipsychotics. Archives of the Balkan Medical Union, vol 48, nr. 4, dec 2013, pp 404-405 <http://umbalk.org/reviews/2013/umb%204'2013%20rezumate.pdf>

8. **Burtea V.**, Ifteni P., Vârgă O., Teodorescu A. Analiza Fluentei Verbale in Episodul Acut de Schizofrenie, Jurnalul Medical Brasovean nr.1- 2013, pp 54-58 [http://webbut.unitbv.ro/jmb/JMB%202013%20nr%201/02\\_05\\_original%20burtea.pdf](http://webbut.unitbv.ro/jmb/JMB%202013%20nr%201/02_05_original%20burtea.pdf)

9. Ifteni P., **Burtea V.**, Teodorescu A. Caracteristicile socio- demografice ale pacientilor cu schizofrenie si sindrom metabolic, Jurnalul Medical Brasovean nr.2- 2013, pp 50-55 [http://webbut.unitbv.ro/jmb/JMB%202013%20nr%202/02\\_08\\_original%20ifteni.pdf](http://webbut.unitbv.ro/jmb/JMB%202013%20nr%202/02_08_original%20ifteni.pdf)

10. Dima L., Ifteni, Pascu A, **Burtea V.**, Moga M. New Theory in Schizophrenia and Implications in Antipsychotics Development. Archives of the Balkan Medical Union, 2014, vol. 49, no. 2, pp. <http://umbalk.org/reviews/2014/2014%20-%202.pdf>

11. **Burtea V.**, Ifteni P., Pascu A. Gender Differences in Major Depression with Metabolic Syndrome. Archives of the Balkan Medical Union, 2014, vol. 49, no. 1, pp. 40-42 <http://umbalk.org/reviews/2014/2014%20-%201.pdf>

12. Moga M.A., Arvătescu C., **Burtea V.**, Spulber R., Pascu A., Țiț D. Review of Statins Treatment in Polycystic Ovary Syndrome. Archives of the Balkan Medical Union in press

13. Moga M.A., Arvătescu C., Anastasiu C., Ungureanu D., Mironescu A., **Burtea V.** Fetal Hydrothorax – a Case Report. Archives of the Balkan Medical Union in press

14. Moga M., Bigiu N., Pascu A., Badea M., **Burtea V.** Polychlorinated Biphenils Impact on Pregnancy. Archives of the Balkan Medical Union, 2014, vol. 49, no. 1, pp. 61-65  
<http://umbalk.org/reviews/2014/umb%201'2014%20rezumate.pdf>

**Criteriu indeplinit**

**2.3 granturi  
/proiecte  
castigate prin  
competitie  
(director  
/responsabil  
proiect)**

***Criterii obligatorii:***

Profesor – minim 3 granturi/proiecte, din care 1 ca director de proiect

**Conferentiar – minim 2 granturi/proiecte, din care 1 ca responsabil de proiect**

***Îndeplinire:***

**Granturi / proiecte - membru**

1. Bioanalytical Methods – Linking Environmental Protection and Public Health – 51388 – IC – 1- 2003-RO- ERASMUS-DISSUC-2, MEMBRU

2. Leonardo da Vinci – Community Vocational Training Action Programme – PMH – PROMENTALHEALTH, Exchange of Competencies for Trainers on Mental Health Promotion – RO/2006/971125/Ex, MEMBRU

3. Matra - Reinforcement of the Integrated System of Extramural Mental Health Care Services in Three Counties in Romania Asociația de Servicii Sociale SCUT-coordonator local, Spitalul de Psihiatrie și Neurlogie Isi II membru - partener, Universitatea Transilvania – partener, MEMBRU

**Granturi / proiecte - Director / responsabil de proiect**

1. Proiect național de cercetare științifică cu terti și Universitatea “Transilvania” nr 23/16.09.2008 cu titlul „Impactul simptomatologiei anxios-depresive asupra densității minerale a osului la subiecții sub 45 de ani”, în valoare de 10150 RON, **DIRECTOR**

2. Proiect internațional de cercetare științifică între BIOLINERX (Israel) și

Universitatea „Transilvania” Brasov cu nr 155/8.01.2009, in valoare de 10500 Euro, Sursa de finantare: BIOLINERX (Israel ), **DIRECTOR**

3.Proiect internațional de cercetare stiintifica intre Stanley Medical Research Institute si Universitatea „Transilvania” Brasov cu nr 6937/28.05.2009, in valoare de 10200 Euro Sursa de finantare: Stanley Medical Research Institute (US), **DIRECTOR**

4. Proiect național de cercetare stiintifica cu terti si Universitatea “Transilvania” nr 6658/22.05.2009 cu titlul „Modelul de tratament al schizofreniei in județul Brașov”, in valoare de 10100 RON Sursa de finantare: Sanofi, **DIRECTOR**

**Criteriu indeplinit**

2.4 articole publicate in rezumat in reviste si volumele unor manifestari stiintifice cu ISBN sau ISSN

**Criterii obligatorii:**

Profesor – minim 8 articole din care 3 in ultimii 5 ani

**Conferentiar – minim 3 articole din care 1 in ultimii 5 ani**

**Îndeplinire:**

**1. Burtea V**, Mosoiu C., Auditory Scene Analysis and Perceptual Streaming in Patient with Schizophrenia. The Journal of the European College of Neuropsychopharmacology, 2005, vol 15 ( Supp. 3 ), pp S525. Abstracts of the 18 ECNP Congress Amsterdam, Netherland, october 22-26,2005

**2. Burtea V**, Sangeorzan L, Rogoza L, Mosoiu C, Nedelcu A, Popescu M, Iliescu M, Munteanu RI, Fraustosolis J, Sireteanu T, Cârstea I, Bagnar G. An Empirical Investigation of Perceived Violence in Communication in Six Different University Settings in Romania, WSEAS nov 07-09, București, România, 2008; pp: 512-517; proceeding indexat ISI.  
<http://www.wseas.us/e-library/conferences/2008/bucharest2/macmese/macmese-S10.pdf>

**3. Rogoza L, Cristea L, Baritz M, Burtea V.** Telemedicine and ethical dilemmas. Proceedings Of The 8th Wseas International Conference On Artificial Intelligence, Knowledge Engineering And Data Bases. Book Series: Artificial Intelligence Series WSEAS 2009, 41-45  
<http://www.wseas.us/e-library/conferences/2009/cambridge/AIKED/AIKED03.pdf>

4. Rogozea L, Miclaus R, Repanovici A, **Burtea V.**, et al. Health promotion – strategies and topics Educating the students from nursing and optometry department. 9th WSEAS International Conference on Education and Educational Technology. SELECTED TOPICS IN EDUCATION AND EDUCATIONAL TECHNOLOGY 2010, 263-267

<http://www.wseas.us/books/2010/Japan/EDU.pdf>

5. Mosoiu C, Sumedrea A.G, **Burtea V.**, Ifteni P. Fuzzy systems approach to symptoms in schizophrenia. Proc. of the 11th WSEAS Int. Conf. On Neural Networks, NN 10. Proceedings of the 11th WSEAS Int. Conf. On Evolutionary Computing, EC '10, Proc. Of the 11th WSEAS Int. Conf. On Fuzzy Systems, FS'10 2010, 268-272

[http://www.wseas.us/e-library/conferences/2010/Iasi/NN\\_ECFS/NNECFs-00.pdf](http://www.wseas.us/e-library/conferences/2010/Iasi/NN_ECFS/NNECFs-00.pdf)

6. Ifteni P., **Burtea V.**, Chirita V., Mosoiu C. The Influence of Metabolic Syndrome in Major Depressive Disorder Outcome. WSEAS Athena, Greece, September 28-30 2009; pp: 438- 440

7. Mosoiu C., **Burtea V.**, Sumedrea A.G., Ifteni P. Syndrome Specification by Factor Analysis in Schizophrenia. WSEAS Athena, Greece, September 28-30 2009; pp: 511-515

8. Ifteni P., **Burtea V.**, Mosoiu C. Prevention of Relapses in the Bipolar I Disorder: a Comparative Study between Quetiapine Monotherapy vs. Quetiapine- Valproate Combined Therapy. WSEAS Athena, Greece, September 28-30 2009; pp: 435- 437

9. Burtea VD., **Burtea V.**, Mosoiu C., Sumedrea AG., Dimensions of Anxiety Symptoms in Romanian Young Adult Subjects from Brasov County. WSEAS Athena, Greece, September 28-30 2009, pp 507-510

[http://www.wseas.us/e-library/conferences/2009/vouliagmeni/ACC MM/ACCMM2-17.pdf](http://www.wseas.us/e-library/conferences/2009/vouliagmeni/ACC_MM/ACCMM2-17.pdf)



10. **Burtea V.**, Mosoiu C., Vârciu M., Leășu F. The Overlap of Depression and Anxiety Symptoms in a Community Sample of Romanian Young Adults. Proceedings of 11th WSEAS International conference on Mathematical and computational methods in science and engineering, September 2009, pp 503-506 <http://www.wseas.us/e-library/conferences/2009/vouliagmeni/ACCMM/ACCMM2-16.pdf>

11. Dima L., Podasca C., Rogozea L., Balescu A., **Burtea V.** Hospital web pages – a Brasov case study. Proceedings of 12th WSEAS International conference on Mathematical and computational methods in science and engineering, November 2010, pp 331-335 <http://www.wseas.us/e-library/conferences/2010/Faro/MACMESE/MACMESE-55.pdf>

12. Ifteni P., **Burtea V.**, Mosoiu C., Rogozea L. Ethic aspects medical information through computers and internet. WSEAS, 2011, pp: 159- 162 <http://www.wseas.us/e-library/conferences/2011/Iasi/EDUTE/EDUTE-28.pdf>

**Criteria indeplinit**

	<b>2.5. proiecte educationale si de formare continua</b>	<i>Îndeplinire:</i>
<b>3</b>	<i>Recunoașterea și impactul activității</i>	<i>Îndeplinire:</i>
	Premii	<i>Îndeplinire:</i>
	Citări in reviste ISI și BDI - 0,05 pct/citare	<i>Îndeplinire:</i>
	3.3 Prezentări invitate în plenul unor manifestări științifice naționale și internaționale	<i>Îndeplinire:</i>

3.4.profesor invitat (exclusive ERASMUS)		
3.5. membru în colectivele de redacție sau comitete științifice, organizator de manifestări științifice	<i>Îndeplinire:</i>	<ol style="list-style-type: none"> <li>1. Comitet de redactie Romanian journal of Psychopharmacology 2003</li> <li>2. Comitet de redactie Jurnalul Medical Brasovean</li> <li>3. Comitet Stiintific National - Simpozionul National de Psihiatrie. Personalitate normala si patologice. Tulburari anxioase si de dispozitie. 2001</li> <li>4. Comitet Stiintific International Conferinta Internationala " Enviornmental Pollution and It's Impact on Public Health" 2008</li> <li>5. Comitetul Stiintific Conferinta Nationala de Psihiatrie 2009</li> <li>6. Comitet Stiintific Onorific Prima Consfatuire Nationala de Istorie a Psihiatriei Romanesti 2009</li> <li>7. Comitet Stiintific National Conference of Biological Psychiatry and Psychopharmacology 2010</li> <li>8. Comitet Stiintific International - International Academic Autumn School " Impact of enviornmental pollution on public health " 2011</li> <li>9.Comitet Stiintific Al IV-Lea Congres National de Psihiatrie 2011</li> </ol>
3.6 recenzor pentru reviste și manifestări științifice naționale și internaționale indexate ISI/BDI	<i>Îndeplinire:</i>	
3.7 membru comisii de doctorat (exclusiv președinte) și abilitare		1. Universitatea de Medicina si Farmacie Craiova, Ordinul Rectorului Universitatii de Medicina si Farmacie Craiova nr. 8/B din 29.06.2010 - membru referent in comisie de sustinere a tezei de doctorat elaborata de Dna Raducanu M. Emilia pentru obtinerea titlului stiintific de Doctor in Medicina.
3.8 experiența de management în cercetare și/sau	<i>Îndeplinire:</i>	<p><b>I. Investigator principal in trialuri internationale.</b></p> <ol style="list-style-type: none"> <li>1.TRIAL 100 – Stamina. An international, multicentre, double- blind, randomised, placebo- controlled study of the safety and efficacy of Seroquel</li> </ol>

- (Quetiapine fumarate) as add-on therapy with lithium and divalproex in the treatment of acute mania. Investigator meeting - Monte Carlo, 23-25.07.2001
2. TRIAL 105 – Stamp 2. An international, multicentre, double-blind, randomised, placebo-controlled study of the safety and efficacy of seroquel (quetiapine fumarate) and lithium as monotherapy in the treatment of acute mania. Investigator meeting - Monte Carlo, 23-25.07.2001
  3. TRIAL RIS-SCP 402. A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Risperidone vs. Quetiapine vs. Placebo in Subjects with an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder. Investigator meeting – Salonic, Grecia, septembrie 2003
  4. EUFEST. The European First Episode Schizophrenia Trial – comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. Investigator meeting – București, noiembrie 2003; Paris, 20.06.2004
  5. TRIAL 10124. A double blind, randomised study of long-term bifeprunox efficacy, safety and tolerability in patients with chronic schizophrenia
  6. TRIAL N3D/FOR-OCA-05. Multicentre, double-blind, placebo controlled, rising dose, parallel group study of the efficacy and tolerability of ocapiridone in schizophrenic patients. Investigator meeting – Colmar, Franța, februarie 2004
  7. TRIAL N3D/FOR-OCA-08. Multicentre, double-blind, placebo controlled, rising dose, parallel group study of the efficacy and tolerability of ocapiridone in schizophrenic patients – extension of N3D/FOR-OCA-05. Investigator meeting – Colmar, Franța, februarie 2004
  8. STAGE. A 24-week, International, Multi-centre, Open-label, Flexible-dose, Randomised, Parallel-Group, Phase IV Study to Compare the Effect on Glucose Metabolism of Quetiapine, Olanzapine and Risperidone in the Treatment of Patients with Schizophrenia. Investigator meeting – Dresda, februarie 2004
  9. REASSURE I. A 6-week, International, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapina Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia. Investigator meeting – Frankfurt, Germania, mai 2004

10. TRIAL RO76477-SCH-1010. A Double Blind, Placebo- Controlled, Randomised Study Evaluating the effect of ER OROS Paliperidone Compared to Placebo on Sleep in Subjects with Schizophrenia
11. TRIAL D1447C00144. Multicenter, randomised, Parallel- group, Double-Blind, Placebo- controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients, 2004
12. TRIAL TRIAL 041023. A Multicenter, randomised, Double- Blind, fixed-dose, 6 weeks trial of the efficacy and safety of asenapine compared with placebo using a haloperidol positive control in subjects with an acute exacerbation of schizophrenia, phase IIIa, 2005-2006
13. TRIAL 041513. A double-blind, flexible dose, positive-controlled, multicenter, long term extension of a randomized trial for subjects who have completed the 6 weeks short term trial 041023; phase IIIa, 2006
14. TRIAL BL – 1020 Phase IIa, 2007-2008. An open-label, multicenter, six-weeks, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizoaffective disorder
15. TRIAL BL – 1020 Phase IIb, 2008-2009. A six week, randomized, double-blind, placebo- controlled, parallel group, multi-center, phase IIb study to determine the efficacy, safety and tolerability of low and high non-overlapping dose ranges of BL-1020 compared to placebo and Risperidone in patients with acute exacerbations of schizophrenia
16. TRIAL ALL-S-01 Phase III, 2009-2010. Allopurinol in schizophrenia: a randomized trial administering Allopurinol vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder
17. TRIAL CL3- 20098-083 Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder.
18. TRIAL P05691 2011 A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel Group, Three week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects with Bipolar I Disorder, Experiencing an Acute Manic or Mixed Episode.

19. TRIAL P05692 2012-2014 A Multicenter, Double-Blind, Fixed-Dose, Long Term Extension Trial, of the Safety of Asenapine in Subjects with Bipolar 1 Disorder who Completed Protocol P05691

20. TRIAL P05688 2012-2014 A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6 Week Trial of the Efficacy and Safety of Asenapine Compared with Placebo Using Olanzapine as an Active Control in Subjects with an Acute Exacerbation of Schizophrenia.

## **II. Sef Catedra de Specialitati Medicale 2008-2012**

## **III. Director de Departament DFPC din anul 2013**

3.9. participare efectivă  
manifestări științifice *Îndeplinire:*